TY - JOUR
T1 - Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy in Patients With Advanced Ovarian Cancer (OVHIPEC-1)
T2 - Final Survival Analysis of a Randomised, Controlled, Phase 3 Trial
AU - Aronson, S. Lot
AU - Lopez-Yurda, Marta
AU - Koole, Simone N.
AU - Schagen Van Leeuwen, Jules H.
AU - Schreuder, Hendrik W.R.
AU - Hermans, Ralph H.M.
AU - De Hingh, Ignace H.J.T.
AU - Van Gent, Mignon D.J.M.
AU - Arts, Henriëtte J.G.
AU - Van Ham, Maaike A.P.C.
AU - Van Dam, Peter A.
AU - Vuylsteke, Peter
AU - Aalbers, Arend G.J.
AU - Verwaal, Victor J.
AU - Van De Vijver, Koen K.
AU - Aaronson, Neil K.
AU - Sonke, Gabe S.
AU - Van Driel, Willemien J.
PY - 2024/2
Y1 - 2024/2
N2 - Although the 5-year survival of patients with advanced ovarian cancer has improved, overall survival at 10 years remains approximately 13%. Hyperthermic intraperitoneal chemotherapy (HIPEC) involves the delivery of chemotherapeutic agents directly into the peritoneum in combination with hyperthermia, which enhances penetration and increases sensitivity to platinum compounds by inducing a transient state of homologous recombination deficiency.
AB - Although the 5-year survival of patients with advanced ovarian cancer has improved, overall survival at 10 years remains approximately 13%. Hyperthermic intraperitoneal chemotherapy (HIPEC) involves the delivery of chemotherapeutic agents directly into the peritoneum in combination with hyperthermia, which enhances penetration and increases sensitivity to platinum compounds by inducing a transient state of homologous recombination deficiency.
UR - https://www.scopus.com/pages/publications/85185761644
U2 - 10.1097/01.ogx.0001008536.08634.9f
DO - 10.1097/01.ogx.0001008536.08634.9f
M3 - Comment/Letter to the editor
AN - SCOPUS:85185761644
SN - 0029-7828
VL - 79
SP - 96
EP - 98
JO - Obstetrical and Gynecological Survey
JF - Obstetrical and Gynecological Survey
IS - 2
ER -